Skip to content Skip to footer
Pasireotide: Benefits, Reviews, Info, Side Effects!
Rx Details
Pasireotide
Signifor, Signifor LAR
Pasireotide
Prescription
Drug
Drugs
Prescription Only
reduction of cortisol levels, treatment of Cushing’s disease, management of acromegaly, potential tumor shrinkage, improvement of symptoms related to hormone overproduction
Abdominal Pain, Bradycardia, Diarrhea, Dizziness, Edema, Fatigue, Gallstones, Hair Loss, Headache, Hyperglycemia, Hypothyroidism, Increased Liver Enzymes, Injection Site Reactions, Nausea
Pasireotide is a medication used primarily to treat Cushing’s disease and acromegaly. The dosage of pasireotide can vary based on the condition being treated, the formulation of the drug, and individual patient factors. Here are some general guidelines: 1. **For Cushing’s Disease:** – **Pasireotide (Signifor) subcutaneous injection:** The typical starting dose is 0.6 mg or 0.9 mg administered twice daily. The dose may be adjusted based on the patient’s response and tolerability. 2. **For Acromegaly:** – **Pasireotide (Signifor LAR) long-acting intramuscular injection:** The usual starting dose is 40 mg administered once every four weeks. The dose may be adjusted based on the patient’s response and tolerability, with a maximum dose of 60 mg every four weeks. It’s important to note that these are general guidelines, and the exact dosage should be determined by a healthcare professional based on individual patient needs and response to treatment. Always consult with a healthcare provider for personalized dosing information.
Cushing’s disease, acromegaly
Pasireotide has a generally safe safety profile.
No interactions found
$1,000 – $2,000
$3,500 for a 30day supply.

A Synopsis of

Pasireotide

Pasireotide is a medication that belongs to a class of drugs known as somatostatin analogs. It is primarily used in the treatment of Cushing’s disease, a rare condition characterized by the overproduction of cortisol in the body. Pasireotide works by binding to somatostatin receptors on the pituitary gland, which helps to reduce the production of adrenocorticotropic hormone (ACTH) and ultimately lower cortisol levels.

This medication is typically administered as an injection and is usually given once a month. It is important to follow your healthcare provider’s instructions carefully when taking pasireotide to ensure optimal results. Common side effects of pasireotide may include nausea, diarrhea, and elevated blood sugar levels. It is important to discuss any concerns or side effects with your healthcare provider.

As with any medication, it is important to weigh the potential benefits of pasireotide against the risks. Your healthcare provider will work with you to determine if pasireotide is the right treatment option for your specific condition. It is also important to inform your healthcare provider of any other medications or supplements you are taking, as they may interact with pasireotide.

Overall, pasireotide can be an effective treatment option for individuals with Cushing’s disease. By working with your healthcare provider and following their guidance, you can manage your condition and improve your quality of life. If you have any questions or concerns about pasireotide, do not hesitate to reach out to your healthcare provider for more information.

RxDb Legal Disclaimer

The information provided on RxDB.net is for informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional, such as a doctor or pharmacist, for any questions or concerns regarding your health, medications, or medical conditions. Reliance on any information provided on this website is solely at your own risk. RxDB.net does not provide medical or pharmaceutical services and is not liable for any decisions made based on the information contained herein.

PAGE LAST UPDATED

Health Education Through Aggregation

Sign up for the Rx Database Newsletter!
Menu
Questions?

Website By Foxco © 2025. All rights reserved.

0
Would love your thoughts, please comment.x
()
x
en_USEN